PIK3CA/AKT1/PTEN alterations are frequently observed in breast cancer, including approximately 50% of patients with hormone receptor-positive (HR+) breast cancers, and contribute towards a negative prognosis and resistance to endocrine therapies [5–9]. Here, AKT1 is linked to breast cancer.